Skip to main content

Table 2 Results relating to clinical change and study attrition.

From: Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

  Months Number of trials Chlorpromazine Placebo RR (95% CI) Test for heterogeneity
    events/total participants   
Relapse 6–24 3 108/202 159/192 0.65 (0.5–9.0) Chi2 7.83, df 2, p = 0.02 I2 = 74.5%*
No global improvement 2–6 13 470/654 406/467 0.76 (0.7–0.9) Chi2 25.4, df 12, p = 0.01 I2 = 52.8%
Leaving the study early 6–24 2 38/254 33/238 1.09 (0.7–1.6) Chi2 0.47, df 1, p = 0.49 I2 = 0%
  1. * no clear cause of heterogeneity found on close re-inspection of trials